AQST Aquestive Therapeutics Inc.

8.01
-0.33  -4%
Previous Close 8.34
Open 8.3
Price To Book -5.8
Market Cap 200,594,142
Shares 25,042,964
Volume 637,463
Short Ratio
Av. Daily Volume 532,554
Stock charts supplied by TradingView

NewsSee all news

  1. Aquestive Therapeutics to Host Investor & Analyst Libervant™ (diazepam) Buccal Film Update Forum at American Epilepsy Society 2019 Annual Meeting

    WARREN, N.J., Dec. 04, 2019 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients' unmet

  2. Aquestive Therapeutics Completes Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Libervant™ (diazepam) Buccal Film for Management of Seizure Clusters

    WARREN, N.J., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients' unmet

  3. Aquestive Therapeutics Announces Poster Presentations of Data on Libervant™ (diazepam) Buccal Film at American Epilepsy Society 2019 Annual Meeting

    Company to Host Scientific Exhibit on Monday, December 9 from 8:00 am ET to 11:00 am ET Company to Host Investor & Analyst Libervant Update Forum and Webcast on Monday, December 9 at 4:00 pm ET WARREN, N.J., Nov.

  4. Aquestive Therapeutics Receives FDA Approval for Exservan™ (riluzole) Oral Film

    WARREN, N.J., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic

  5. Aquestive Therapeutics Licenses Riluzole Oral Film to Zambon for Development and Commercialization in the EU for Patients with ALS

    WARREN, N.J., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients' unmet

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

NDA filing due by January 2020.
KP415
ADHD
FDA Approval announced November 22, 2019.
Exservan (riluzole) Oral Film
Amyotrophic Lateral Sclerosis
Tentative approval issued August 31, 2018. Full approval issued November 2, 2018.
Sympazan
Lennox-Gastaut Syndrome
Completion of rolling NDA announced December 2, 2019.
Libervant - AQST-203
Epileptic seizures
CRL issued November 16, 2018.
AQST-119
Erectile dysfunction
CRL issued January 30, 2019 through partner Sunovion (private company). NDA to be refiled 4Q 2019.
APL-130277
Parkinson’s Disease with motor fluctuations
Phase 1 trial has been completed - September 30, 2019 - well tolerated.
AQST-108
Anaphylaxis

Latest News

  1. Aquestive Therapeutics to Host Investor & Analyst Libervant™ (diazepam) Buccal Film Update Forum at American Epilepsy Society 2019 Annual Meeting

    WARREN, N.J., Dec. 04, 2019 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients' unmet

  2. Aquestive Therapeutics Completes Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Libervant™ (diazepam) Buccal Film for Management of Seizure Clusters

    WARREN, N.J., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients' unmet

  3. Aquestive Therapeutics Announces Poster Presentations of Data on Libervant™ (diazepam) Buccal Film at American Epilepsy Society 2019 Annual Meeting

    Company to Host Scientific Exhibit on Monday, December 9 from 8:00 am ET to 11:00 am ET Company to Host Investor & Analyst Libervant Update Forum and Webcast on Monday, December 9 at 4:00 pm ET WARREN, N.J., Nov.

  4. Aquestive Therapeutics Receives FDA Approval for Exservan™ (riluzole) Oral Film

    WARREN, N.J., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to solve therapeutic

  5. Aquestive Therapeutics Licenses Riluzole Oral Film to Zambon for Development and Commercialization in the EU for Patients with ALS

    WARREN, N.J., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients' unmet

  6. Aquestive Therapeutics Reports Third Quarter 2019 Financial Results and Raises 2019 Guidance

    Increases full year 2019 revenue and earnings guidanceExpects to complete its rolling New Drug Application (NDA) submission for Libervant™ (diazepam) Buccal Film around the end of November 2019Reported successful

  7. Aquestive Therapeutics to Attend Two Upcoming Investor Conferences

    WARREN, N.J., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that meet patients' unmet